Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Income from Continuing Operations: 2021-2025

Historic Income from Continuing Operations for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $79.4 million.

  • Krystal Biotech's Income from Continuing Operations rose 192.12% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 279.88%. This contributed to the annual value of $89.2 million for FY2024, which is 715.58% up from last year.
  • Per Krystal Biotech's latest filing, its Income from Continuing Operations stood at $79.4 million for Q3 2025, which was up 107.05% from $38.3 million recorded in Q2 2025.
  • Krystal Biotech's Income from Continuing Operations' 5-year high stood at $80.7 million during Q3 2023, with a 5-year trough of -$50.0 million in Q1 2022.
  • In the last 3 years, Krystal Biotech's Income from Continuing Operations had a median value of $27.2 million in 2024 and averaged $21.9 million.
  • As far as peak fluctuations go, Krystal Biotech's Income from Continuing Operations crashed by 215.99% in 2022, and later spiked by 3,730.15% in 2025.
  • Quarterly analysis of 5 years shows Krystal Biotech's Income from Continuing Operations stood at -$21.8 million in 2021, then slumped by 46.99% to -$32.1 million in 2022, then spiked by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then surged by 192.12% to $79.4 million in 2025.
  • Its Income from Continuing Operations was $79.4 million in Q3 2025, compared to $38.3 million in Q2 2025 and $35.7 million in Q1 2025.